YIFAN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.06 CNY | +1.01% |
|
+19.49% | -11.64% |
| 25/04 | Yifan Unit's Allergy Drug Passes China Regulatory Test, Stock Price Jumps | MT |
| 25/04 | Yifan Pharmaceutical's Unit Gets Nod to Register Nimodipine Injection | MT |
| Sales 2024 * | 5.22B 721M 60.14B | Sales 2025 * | 6.5B 897M 74.86B | Capitalization | 15.89B 2.19B 183B |
|---|---|---|---|---|---|
| Net income 2024 * | 560M 77.33M 6.45B | Net income 2025 * | 742M 102M 8.55B | EV / Sales 2024 * | 3.04 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.44 x |
| P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
21.5
x | Employees | 4,230 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.82% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.01% | ||
| 1 week | +19.49% | ||
| Current month | +17.87% | ||
| 1 month | +18.84% | ||
| 3 months | +5.41% | ||
| 6 months | +0.46% | ||
| Current year | -11.64% |
1 week
11.42
13.23
1 month
10.8513.23
Current year
9.1115.30
1 year
9.1116.86
3 years
9.1121.26
5 years
9.1134.36
10 years
8.0034.36
| Managers | Title | Age | Since |
|---|---|---|---|
Xian Feng Cheng
CHM | Chairman | 56 | 15/14/15 |
Guo Han Xu
CHM | Chairman | 57 | 01/14/01 |
De Qi Feng
BRD | Director/Board Member | 45 | 28/16/28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hongquan Liu
BRD | Director/Board Member | 65 | 27/20/27 |
Xian Feng Cheng
CHM | Chairman | 56 | 15/14/15 |
Ben Yu Zhou
BRD | Director/Board Member | 51 | 15/14/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 13.06 | +1.01% | 16,210,880 |
| 25/24/25 | 12.93 | +2.13% | 18,631,340 |
| 24/24/24 | 12.66 | +5.32% | 32,231,680 |
| 23/24/23 | 12.02 | +5.81% | 18,538,010 |
| 22/24/22 | 11.36 | +3.93% | 14,487,100 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.06
CNY
Average target price
18.33
CNY
Spread / Average Target
+40.35%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.64% | 2.19B | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +11.60% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- 002019 Stock
